Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
Stock Information for Capricor Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.